Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 3:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 1,383 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: A PROTEIN level Clear all
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Study of 2.0 mg Ranibizumab in Subjects With Ischemic Central Retinal Vein Occlusion (RAVE2)

NCT01225146
View directory record Official record
Conditions
Ischemia, Retinal Vein Occlusion, Pathologic Processes, Retinal Diseases, Eye Diseases
Interventions
ranibizumab
Drug
Lead sponsor
David M. Brown, M.D.
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 14, 2017 · Synced Oct 14, 2026, 3:37 AM EDT
Terminated Phase 3 Interventional Results available

Muscadine Plus (MPX) In Men With Prostate Cancer

NCT03535675
View directory record Official record
Conditions
Adenocarcinoma of the Prostate
Interventions
Muscadine Plus, Placebos
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 99 Years · Male only
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
13
States / cities
Duarte, California • La Jolla, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated May 22, 2023 · Synced Oct 14, 2026, 3:37 AM EDT
Recruiting Phase 4 Interventional

Staphylococcus Aureus Network Adaptive Platform Trial

NCT05137119
View directory record Official record
Conditions
Staphylococcus Aureus Bacteremia
Interventions
Cefazolin, Penicillin, Clindamycin, Vancomycin, Effectiveness of early switch to oral antibiotics, Whole body FDG PET/CT Imaging
Drug · Other · Radiation
Lead sponsor
University of Melbourne
Other
Eligibility
Not listed
Enrollment
8,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 14, 2026, 3:37 AM EDT
Withdrawn Phase 1 Interventional

PF-07225570 Alone or in Combination With an Anti-PD-1 Antibody in Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

NCT05259397
View directory record Official record
Conditions
Bladder Cancer
Interventions
PF-07225570, sasanlimab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 8, 2023 · Synced Oct 14, 2026, 3:37 AM EDT
Completed Phase 1 Interventional

Study of Cisplatin and Pemetrexed in Combination With Panobinostat in Solid Tumors

NCT01336842
View directory record Official record
Conditions
Solid Tumors, Non-Small Cell Lung Cancer (NSCLC)
Interventions
Panobinostat, Cisplatin, Pemetrexed
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
2
States / cities
Sacramento, California • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 9, 2018 · Synced Oct 14, 2026, 3:37 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of DB-1310 in Advanced/Metastatic Solid Tumors

NCT05785741
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
DB-1310, Trastuzumab, Osimertinib, capecitabine
Drug
Lead sponsor
DualityBio Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
15
States / cities
Sacramento, California • Santa Monica, California • Coral Gables, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 14, 2026, 3:37 AM EDT
Completed Phase 2 Interventional Results available

Gossypol in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme

NCT00540722
View directory record Official record
Conditions
Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
Interventions
R-(-)-gossypol acetic acid, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
8
States / cities
Birmingham, Alabama • Tampa, Florida • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2017 · Synced Oct 14, 2026, 3:37 AM EDT
Terminated Phase 1 Interventional Results available

A Study of Dasatinib, Cetuximab and Radiation With or Without Cisplatin in HNSCC

NCT00882583
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Cetuximab, Dasatinib, Cisplatin, Radiation Therapy
Drug · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
2
States / cities
Baltimore, Maryland • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 9, 2019 · Synced Oct 14, 2026, 3:37 AM EDT
Completed Phase 1 Interventional

Study To Examine Toxicity Of Allogeneic Stem Cell Transplantation For Relapsed Or Therapy Refractory Ewings Sarcoma

NCT02472392
View directory record Official record
Conditions
EWINGS SARCOMA
Interventions
Rabbit anti-thymocyte globulin, Busulfan, Melphalan, Fludarabine, Cyclophosphamide
Drug
Lead sponsor
University of Louisville
Other
Eligibility
Up to 30 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Oct 14, 2026, 3:37 AM EDT
Recruiting Phase 1 Interventional

Tegavivint With Gemcitabine in Patients With Relapsed or Refractory Osteosarcoma

NCT07144254
View directory record Official record
Conditions
Osteosarcoma Recurrent, Osteosarcoma in Children, Relapsed Osteosarcoma, Refractory Osteosarcoma
Interventions
Tegavivint, Gemcitabine
Drug
Lead sponsor
Emory University
Other
Eligibility
1 Year to 30 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 14, 2026, 3:37 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of OMT on Functional Outcomes and Anti-inflammatory Biomarkers in Mild to Moderate Traumatic Brain Injury

NCT03163901
View directory record Official record
Conditions
Vestibular Disorder, Headache, Traumatic Brain Injury
Interventions
Osteopathic Manipulative Treatment
Other
Lead sponsor
Michigan State University
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Mason, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 24, 2020 · Synced Oct 14, 2026, 3:37 AM EDT
Completed Phase 4 Interventional Results available

Immunologic Basis of Anti-IgE Therapy (Study II: On Patients With Asthma)

NCT00367016
View directory record Official record
Conditions
Asthma, Allergic Rhinitis, Atopic Dermatitis
Interventions
Omalizumab, Placebo
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 55 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jul 13, 2021 · Synced Oct 14, 2026, 3:37 AM EDT
Completed Phase 1 Interventional

Study of DS-8273a With Nivolumab in Unresectable Stage III or Stage IV Melanoma

NCT02983006
View directory record Official record
Conditions
Melanoma
Interventions
DS-8273a, Nivolumab
Biological
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 18, 2021 · Synced Oct 14, 2026, 3:37 AM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Release Kinetics of rhBMP-2 Using E-PRF as an Autologous Carrier: An In Vitro Analysis

NCT04670965
View directory record Official record
Conditions
Bone Loss
Interventions
E-PRF/rhBMP-2 (similar ratios), E-PRF/ACS/rhBMP-2, rhBMP-2/E-PRF, E-PRF only
Biological
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 99 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 14, 2026, 3:37 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy

NCT03674411
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Biphenotypic/Undifferentiated Leukemia, Chronic Myelogenous Leukemia, Myelodysplasia, Relapsed Large Cell Lymphoma, Mantle Cell Lymphoma, Hodgkin Lymphoma, Burkitt Lymphoma, Relapsed T-Cell Lymphoma, Lymphoplasmacytic Lymphoma
Interventions
Fludarabine (FLU), Cyclophosphamide (CY), Total Body Irradiation (TBI), Tacrolimus (Tac), Mycophenolate Mofetil (MMF), Granulocyte Colony-Stimulating Factor (G-CSF), Busulfan (BU), Melphalan, MGTA 456 Infusion
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 55 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Oct 14, 2026, 3:37 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Velcade, Trisenox, Vitamin C and Melphalan for Myeloma Patients

NCT00469209
View directory record Official record
Conditions
Myeloma
Interventions
Trisenox (Arsenic Trioxide), Velcade (Bortezomib), Melphalan, Vitamin C (Ascorbic Acid)
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 24, 2020 · Synced Oct 14, 2026, 3:37 AM EDT
Completed Phase 3 Interventional

Filgrastim Plus Chemotherapy Compared With Filgrastim Alone In Treating Women Undergoing Peripheral Stem Cell Transplantation For Breast Cancer

NCT00002836
View directory record Official record
Conditions
Breast Cancer
Interventions
Filgrastim (G-CSF), Carmustine, Cisplatin, Cyclophosphamide (CTX), Etoposide, Thiotepa, Peripheral Blood Stem Cell Transplantation
Biological · Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2006
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 6, 2018 · Synced Oct 14, 2026, 3:37 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Radiation Therapy With Combination Immunotherapy for Relapsed/Refractory Metastatic Melanoma

NCT03297463
View directory record Official record
Conditions
Metastatic Melanoma, Pulmonary Metastases, Hepatic Metastases, Brain Metastases
Interventions
Interleukin-2 & Ipilimumab (P-Ib), Interleukin-2 & Ipilimumab (P-II)
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 1, 2018 · Synced Oct 14, 2026, 3:37 AM EDT
Recruiting Early Phase 1 Interventional

Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in Melanoma

NCT05498792
View directory record Official record
Conditions
Locally Advanced or Metastatic Melanoma
Interventions
CBL0137, Ipilimumab, Nivolumab
Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 14, 2026, 3:37 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

New Daily Persistent Headache Biomarkers Study

NCT04260087
View directory record Official record
Conditions
New Daily Persistent Headache, New Daily Persistent Headache (NDPH)
Interventions
Not listed
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Mar 3, 2022 · Synced Oct 14, 2026, 3:37 AM EDT
Completed Phase 2 Interventional Results available

Hematopoietic Cell Transplantation for Pediatric Patients With Hematologic Malignancies

NCT00795132
View directory record Official record
Conditions
Acute Leukaemia, Chronic Disease, Leukemia, Myelodysplasia, Lymphoma
Interventions
Busulfan, Anti-Thymocyte Globulin, Fludarabine, Cyclosporine, Mycophenolate mofetil
Drug
Lead sponsor
University of Utah
Other
Eligibility
Up to 21 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 30, 2013 · Synced Oct 14, 2026, 3:37 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Assessment of Algorithm-Based Hydroxyurea Dosing on Fetal Hemoglobin Response, Acute Complications, and Organ Function in People With Sickle Cell Disease

NCT02225132
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Hydroxyurea
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
15 Years to 99 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 6, 2019 · Synced Oct 14, 2026, 3:37 AM EDT
Completed Phase 1Phase 2 Interventional

Study of DF1001 in Patients With Advanced Solid Tumors

NCT04143711
View directory record Official record
Conditions
Solid Tumor, Adult
Interventions
DF1001, Nivolumab, Nab paclitaxel, Sacituzumab Govitecan-hziy
Drug
Lead sponsor
Dragonfly Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
16
States / cities
Irvine, California • Los Angeles, California • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Oct 14, 2026, 3:37 AM EDT
Terminated Not applicable Interventional Results available

Busulfan and Cyclophosphamide Followed By ALLO BMT

NCT01685411
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions
Allopurinol, Keppra, Busulfan, Cyclophosphamide, Tacrolimus, Mycophenolate mofetil, Allogeneic hematopoietic stem cell transplant, Filgrastim, antithymocyte globulin
Drug · Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 44 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 13, 2021 · Synced Oct 14, 2026, 3:37 AM EDT